Archives of Cardiovascular Diseases最新文献

{"title":"Response to letters by Sathian et al. and Yue et al. regarding \"Transfusion and coagulation management in acute type A aortic dissection\": Thromboelastography and intraoperative transfusion strategy.","authors":"Philipp Pfeiffer, Daniel-Sebastian Dohle","doi":"10.1016/j.acvd.2025.09.002","DOIUrl":"https://doi.org/10.1016/j.acvd.2025.09.002","url":null,"abstract":"","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145253923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Geographic and demographic disparities in left-ventricular failure mortality, 1999-2020, with forecasts to 2040: A nationwide US analysis.","authors":"Abdalhakim Shubietah, Mohamed S Elgendy, Hosam I Taha, Ameer Awashra, Mohammad Alqadi, Emmanuel Olumuyide, Mohammad O Abdelhafez, Jehad Zeidalkilani, Hasan Munshi, Qutaiba Qafisheh, Muath A Baniowda, Mohammad Ghannam, Mohammed Tareq Mutar","doi":"10.1016/j.acvd.2025.08.012","DOIUrl":"https://doi.org/10.1016/j.acvd.2025.08.012","url":null,"abstract":"","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145253912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combination of a proximity catheterization laboratory and high-volume operators is associated with improved outcome after primary percutaneous coronary intervention.","authors":"Farzin Beygui, Boudjema Ouazar, Lin Schwob, Adrien Lemaitre, Katrien Blanchart, Mathieu Bignon, Rémi Sbatier, Chloé Péron, Guillaume Malcor, Vincent Roule","doi":"10.1016/j.acvd.2025.08.011","DOIUrl":"https://doi.org/10.1016/j.acvd.2025.08.011","url":null,"abstract":"","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145152014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing oral low-density lipoprotein cholesterol-lowering therapy in statin-intolerant patients: A simulation study in France.","authors":"Francois Schiele, Michel Farnier, Bénédicte Borsik","doi":"10.1016/j.acvd.2025.08.008","DOIUrl":"https://doi.org/10.1016/j.acvd.2025.08.008","url":null,"abstract":"<p><strong>Background: </strong>Lipid-lowering therapies effectively reduce low-density lipoprotein cholesterol concentrations and the risk of cardiovascular events, but barriers such as statin intolerance, non-adherence and discontinuation can leave patients at risk.</p><p><strong>Aim: </strong>This study characterized statin-intolerant patients in France, and modelled the low-density lipoprotein cholesterol-lowering effects of ezetimibe and bempedoic acid for those at elevated cardiovascular risk.</p><p><strong>Methods: </strong>Patients were identified based on IQVIA electronic medical records from 1200 general practitioners (September 2022 to August 2023), and this sample was extrapolated to represent the French population. Patients were identified as at high or very high probability of statin intolerance based on statin-associated muscle symptoms, statin downtitration or intermittent dosing/statin switch. The low-density lipoprotein cholesterol-lowering effect of stepwise addition of ezetimibe and bempedoic acid was modelled using a Monte Carlo simulation.</p><p><strong>Results: </strong>Among patients at high or very high cardiovascular risk, 478,370 had statin intolerance: 54.5% at high and 45.5% at very high probability. Overall, 3.6% of patients were not receiving lipid-lowering therapy; most were receiving monotherapy with statins (46.8%) or ezetimibe (24.6%), and 24.4% were receiving a statin+ezetimibe. Of 179,458 patients with a low-density lipoprotein cholesterol result within 12 months and who received lipid-lowering therapy within 3.5 months of the index date, 90% (n=160,633) were not at low-density lipoprotein cholesterol goal at simulation baseline. In this population, adding ezetimibe reduced the mean low-density lipoprotein cholesterol concentration from 127 to 112mg/dL, with a 10.7% increase in goal attainment. Adding bempedoic acid in patients not at goal after ezetimibe further decreased the low-density lipoprotein cholesterol concentration to 86mg/dL, increasing goal attainment to 39.1%.</p><p><strong>Conclusions: </strong>Most (90%) statin-intolerant patients in France do not meet low-density lipoprotein cholesterol goals, emphasizing the need for therapeutic strategies and evidence-based guidelines to improve outcomes. This simulation suggests that treatment escalation could increase low-density lipoprotein cholesterol goal attainment to ∼11% with ezetimibe, and to ∼40% with ezetimibe+bempedoic acid.</p>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145182367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Snare catheter technique in complex transcatheter aortic valve implantation procedures.","authors":"Anthony Mezier, Nicolas Combaret, Andrea Innorta, Nicolas d'Ostrevy, Christophe Saint Etienne, Geraud Souteyrand","doi":"10.1016/j.acvd.2025.08.009","DOIUrl":"https://doi.org/10.1016/j.acvd.2025.08.009","url":null,"abstract":"<p><strong>Background: </strong>Transcatheter aortic valve implantation is challenged by the anatomy and calcification of the arteries, aortic arch and aortic valve.</p><p><strong>Aim: </strong>To describe successful complex transcatheter aortic valve implantation with the use of a snare catheter, where other standard techniques have failed.</p><p><strong>Methods: </strong>From the database of 660 transcatheter aortic valve implantation procedures performed at the Clermont-Ferrand University Hospital between 01 February 2023 and 31 August 2024, we report the use of a snare catheter in five complex procedures with transcatheter heart valve advancement failure: two cases of failure to cross the aortic arch with a self-expandable transcatheter heart valve using standard techniques; one case of a horizontal aorta with failed advancement of a self-expandable transcatheter heart valve; a challenging case with significant calcification in the right coronary cusp impeding balloon-expandable transcatheter heart valve progression and crossing the native aortic valve; and another challenging case where the frame of an aortic bioprosthesis prevented the advancement of a self-expandable transcatheter heart valve.</p><p><strong>Results: </strong>During all these procedures, the use of a snare catheter enabled the challenges of advancement to be overcome, whether within the aortic arch or a horizontal aorta, or when there were difficulties in crossing a native aortic valve or a bioprosthetic aortic valve, thereby allowing the successful implantation of the transcatheter heart valve.</p><p><strong>Conclusions: </strong>The snare catheter strategy is an effective option for performing complex transcatheter aortic valve implantation procedures, specifically when crossing the aortic arch, a horizontal aorta, the aortic valve or an aortic bioprosthesis, and it is possible to use this technique while using the same access site for self-expandable transcatheter heart valve implantation.</p>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145214578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical impact of congestion in patients admitted for cardiogenic shock.","authors":"Miloud Cherbi, François Roubille, Eric Bonnefoy, Paul Gautier, Etienne Puymirat, Guillaume Baudry, Bruno Levy, Pascal Lim, Laurent Bonello, Hamid Merdji, Meyer Elbaz, Clément Delmas","doi":"10.1016/j.acvd.2025.08.006","DOIUrl":"https://doi.org/10.1016/j.acvd.2025.08.006","url":null,"abstract":"<p><strong>Background: </strong>Recent guidelines have proposed dichotomizing acute heart failure and cardiogenic shock phenotypes based on signs/symptoms of hypoperfusion/congestion.</p><p><strong>Aim: </strong>We aimed to assess the prognostic significance of congestion and its early evolution during the first 24hours in a nationwide cardiogenic shock cohort.</p><p><strong>Methods: </strong>FRENSHOCK was a prospective registry including 772 patients with cardiogenic shock from 49 centres. Patients were classified as cold and wet or cold and dry according to congestive signs. Death at 30days was analysed according to baseline phenotype.</p><p><strong>Results: </strong>Among 593 patients with cardiogenic shock included, 70.7% were male; the median age was 67.0 (58.0-77.0) years, and 521 patients (87.9%) presented with congestion. Congestive patients had higher rates of previous cardiac disease (60.5% vs. 43.1%; P<0.01) and chronic kidney disease (24.2% vs. 12.5%; P=0.04). No differences were found regarding Society for Cardiovascular Angiography and Interventions class distribution and lactate concentrations. Congestion was associated with an increased 30-day all-cause death rate (hazard ratio: 1.99, 95% confidence interval: 1.05-3.78; P=0.04), particularly among patients with persistent congestion beyond 24hours (hazard ratio: 2.29, 95% confidence interval: 1.20-4.36; P=0.01). Conversely, patients with resolved congestion at 24hours had similar outcomes to non-congestive patients (hazard ratio: 0.76, confidence interval: 0.31-1.88; P=0.56). The negative impact of congestion was confirmed in multivariable Cox regression analysis.</p><p><strong>Conclusions: </strong>Congestion and its persistence beyond 24hours of management are frequent in patients with cardiogenic shock, and are significantly associated with an increased 30-day all-cause death rate, which may reflect either a direct harmful effect of congestion or difficulties in achieving decongestion in sicker patients. Further studies are warranted to clarify optimal decongestion strategies in patients with cardiogenic shock.</p>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145088258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vaccination is as efficient as a cardiovascular drug! An editorial discussion of vaccination as \"the new pillar in cardiovascular prevention\".","authors":"François Roubille, Paul Loubet","doi":"10.1016/j.acvd.2025.08.007","DOIUrl":"https://doi.org/10.1016/j.acvd.2025.08.007","url":null,"abstract":"","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145103201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial intelligence in cardiovascular medicine: An exoskeleton for perception, reasoning and action.","authors":"Louis-Marie Desroche, Antonin Trimaille, Thierry Garban, Claire Bouleti","doi":"10.1016/j.acvd.2025.07.012","DOIUrl":"https://doi.org/10.1016/j.acvd.2025.07.012","url":null,"abstract":"<p><p>Cardiovascular diseases are a leading cause of morbidity and death, necessitating advanced tools for early diagnosis and personalized care. Artificial intelligence could contribute to transform cardiology through a Perception, Reasoning and Action framework. In the Perception phase, artificial intelligence can improve data acquisition. The Reasoning stage involves artificial intelligence-driven data analysis, integrating large datasets to support clinical decision-making and personalized treatment plans. In the Action phase, artificial intelligence optimizes therapeutic interventions, automates clinical workflows and enhances patient engagement. Artificial intelligence might therefore free up time for cardiologists to focus more on direct patient care and less on data acquisition and analysis, although their supervision remains essential. This review also addresses the technical and ethical challenges of artificial intelligence, including quality of datasets, algorithmic bias, the need for explainable artificial intelligence and data privacy, while exploring future perspectives, such as quantum computing and interdisciplinary collaboration. By addressing these challenges, artificial intelligence has the potential to revolutionize cardiology by enhancing diagnostic precision, advancing risk prediction, optimizing healthcare delivery and improving therapeutic outcomes on a global scale.</p>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145093042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-revenue analysis of using a haemoadsorbent membrane in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass and ticagrelor.","authors":"Benjamin Mathat, Youssouf Compaore, Charles-Henri David, Valery-Pierre Riche, Maël Ryan, Mickaël Vourc'h, Nicolas Mauduit, Johann Clouet, Julien Cadiet, Fabien Nativel","doi":"10.1016/j.acvd.2025.07.011","DOIUrl":"https://doi.org/10.1016/j.acvd.2025.07.011","url":null,"abstract":"<p><strong>Background: </strong>Patients with acute coronary syndrome requiring coronary artery bypass graft surgery while on ticagrelor face a high risk of perioperative bleeding because of its strong antiplatelet effect. The Cytosorb® haemoadsorbent membrane (CytoSorbents Corporation, Princeton, NJ, USA), which is CE marked for ticagrelor removal, may help to mitigate this risk.</p><p><strong>Aim: </strong>To evaluate the cost-revenue impact of the use of Cytosorb® membrane over two different time periods in a high-volume French hospital.</p><p><strong>Methods: </strong>A retrospective cohort of patients who underwent coronary artery bypass grafting with ticagrelor without the use of Cytosorb® and a prospective cohort of patients of the same type undergoing coronary artery bypass grafting with the use of Cytosorb® were compared. The primary outcome was the budget impact of using Cytosorb® in patients undergoing coronary artery bypass grafting with ticagrelor. Secondary outcomes included morbidity criteria and the length of stay in different hospital departments.</p><p><strong>Results: </strong>Among 40 patients, the cost difference favoured the cohort without Cytosorb® by €2670. However, the Cytosorb® group generated €635 more revenue per patient. Operative variables (duration, cardiopulmonary bypass time, transfusions) were similar, but the Cytosorb® group had a shorter stay in the intensive care unit. Sensitivity analysis highlighted membrane cost as the most influential factor in the overall cost difference.</p><p><strong>Conclusion: </strong>In the French financial context, the use of the Cytosorb® in coronary artery bypass graft surgery with ticagrelor leads to additional costs, despite a slight revenue increase and the potential benefit of a shorter stay in the intensive care unit.</p>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145031281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unveiling facilitators and barriers to artificial intelligence implementation in cardiac healthcare: Rationale and design of the INSIGHT-AI France study, from the Artificial Intelligence Working Group and the National College of Cardiologists in Training of the French Society of Cardiology.","authors":"Antonin Trimaille, Stéphane Lafitte, Floran Begue, Gauthier Beuque, Orianne Weizman, Paul Lucain, Nabil Bouali, Thierry Garban, Marc Villaceque, Jérémie Barraud, Cyril Ferdynus, Louis-Marie Desroche","doi":"10.1016/j.acvd.2025.06.078","DOIUrl":"https://doi.org/10.1016/j.acvd.2025.06.078","url":null,"abstract":"<p><strong>Background: </strong>Artificial intelligence has emerged as a promising tool to optimize patient care in the field of cardiovascular medicine. However, data on its adoption and utilization by healthcare professionals are scarce.</p><p><strong>Aim: </strong>To explore the factors that support or hinder the adoption of artificial intelligence in cardiology in France.</p><p><strong>Methods: </strong>The INSIGHT-AI France study is a two-wave longitudinal panel survey recontacting the same individuals after 12 months, targeting professionals involved in the management of patients with cardiovascular diseases, including senior cardiologists, residents, nurses, technicians, engineers and decision-makers involved in artificial intelligence development. Participants from academic, public non-academic and private hospitals were recruited using a stratified sampling approach to capture diverse perspectives. Data were collected via SKEZIA, a platform compliant with the General Data Protection Regulation, with secure authentication and longitudinal tracking capabilities. The baseline survey, distributed from December 2024 to March 2025, assessed knowledge, attitudes, beliefs and practices related to artificial intelligence in cardiology. A follow-up survey will be conducted 12 months later to evaluate changes over time. The survey was developed by a scientific committee, with feedback from artificial intelligence and cardiology experts, and was pilot-tested for feasibility. Statistical analyses will include mixed-effects models and regression analyses.</p><p><strong>Conclusions: </strong>This is the first study designed to explore the acceptance and limitation of artificial intelligence use in cardiovascular medicine in France. By identifying key facilitators and barriers, this study aims to inform strategic initiatives for more effective and equitable artificial intelligence implementation in French-speaking healthcare systems.</p>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145031201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}